Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) was the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 42,600 shares, a growth of 23.1% from the July 31st total of 34,600 shares. Based on an average daily volume of 24,900 shares, the short-interest ratio is presently 1.7 days.
Bioasis Technologies Price Performance
Shares of OTCMKTS BIOAF remained flat at $0.12 during mid-day trading on Friday. Bioasis Technologies has a 12 month low of $0.10 and a 12 month high of $0.28. The stock has a market capitalization of $9.53 million, a P/E ratio of -3.00 and a beta of 0.19. The company's 50 day simple moving average is $0.12 and its 200 day simple moving average is $0.16.
Get Bioasis Technologies alerts:Bioasis Technologies (OTCMKTS:BIOAF – Get Rating) last posted its quarterly earnings data on Tuesday, June 14th. The company reported ($0.01) EPS for the quarter. As a group, equities research analysts forecast that Bioasis Technologies will post -0.05 EPS for the current fiscal year.
About Bioasis Technologies
(Get Rating)
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases.
Read More
- Get a free copy of the StockNews.com research report on Bioasis Technologies (BIOAF)
- Why This Dip in Advanced Auto Parts May be an Opportunity
- MarketBeat: Week in Review 8/22 – 8/26
- Institutional Buying Put A Bottom In Marvell Technology
- Dell Stock Retreats On Weaker Sales, Falls Into Value Terrirtory
- 3 Reasons Dollar General's Rally Has Legs
Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
